个人简介
医学博士，从事血液肿瘤的基础和临床转化研究，承担国家自然科学基金青年项目等多项课题，以第一/通讯作者在血液学TOP期刊Leukemia、Nature子刊发表SCI论文十余篇，获2022年全国“35 under 35”优秀青年肿瘤医生奖。
专业擅长
擅长白血病、淋巴瘤、多发性骨髓瘤等血液肿瘤的化疗、靶向治疗和免疫治疗，倡导血液病患者全程管理和精准治疗。
研究方向
致力于急淋白血病耐药机制和临床转化性研究。
成果奖项：（近五年主要成果及奖励情况）
(1) Xie M, Yang A, Ma J, Wu M, Xu H, Wu K, Jin Y, Xie Y. Akt2 mediates glucocorticoid resistance in lymphoid malignancies through FoxO3a/Bim axis and serves as a direct target for resistance reversal. Cell Death Dis, 2019, 9: 1013.
(2) Yang C, Xie M, Zhang K, Liu H, Liang A, Young KH, Qian W. Risk of HBV reactivation post CD19-CAR-T cell therapy in DLBCL patients with concomitant chronic HBV infection. Leukemia, 2020, 34: 3055-3059.
(3) Xie M, Wang L, Jiang Q, Luo X, Zhao X, Li X, Jin J, Ye X, Zhao K. Significance of initial, interim and end-of-therapy (18)F-FDG PET/CT for predicting transformation risk in follicular lymphoma. Cancer Cell Int, 2021, 21: 394.
(4) Xie M, Huang X, Ye X, Qian W. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma. Int Immunopharmacol, 2019, 77: 105999.
(5) Xie M, Jiang Q, Zhao S, Zhao J, Ye X, Qian W. Prognostic value of tissue- infiltrating immune cells in tumor microenvironment of follicular lymphoma: A meta-analysis. Int Immunopharmacol, 2020, 85: 106684.
(6) Lei W, Xie M, Jiang Q, Xu N, Li P, Liang A, Young KH, Qian W. Treatment-Related Adverse Events of Chimeric Antigen Receptor T-Cell (CAR T) in Clinical Trials: A Systematic Review and Meta-Analysis. Cancers (Basel), 2021, 13: 3912.
社会任职
中国临床肿瘤学会（CSCO） 会员
